Medline (NASDAQ:MDLN) Stock Crosses Above 200 Day Moving Average – What’s Next?

Medline (NASDAQ:MDLN) passed above its two hundred day moving average during trading on Wednesday. The stock has a two hundred day moving average of $39.53 and traded as high as $40.80. Medline shares last traded at $40.35, with a volume of 25,464,548 shares traded.

Medline News Summary

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Medline reported third-quarter EPS of $0.44, topping the $0.32 consensus estimate, on revenue of $7.86 billion. Coverage also highlighted rising net sales and an EPS beat of about 27%. Medline Q3 results
• Positive Sentiment: The company raised its full-year growth outlook, supporting expectations for continued business momentum. It also announced $1 billion in share buybacks, which could support demand for the stock. Q3 earnings and outlook Buyback coverage
• Neutral Sentiment: Some coverage said quarterly profit fell, while Medline reaffirmed its fiscal 2026 adjusted EBITDA outlook. That tempers the earnings beat but indicates no change to that profitability forecast. Profit and EBITDA outlook
• Positive Sentiment: Health Future renewed its prime-vendor agreement with Medline, extending an existing customer relationship. Prime-vendor agreement renewal
• Negative Sentiment: A law firm announced an investigation into potential securities fraud related to product-quality issues and prior stock declines. This is an investigation announcement, not a finding of wrongdoing, but it adds legal and reputational risk. Investigation announcement

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on MDLN shares. Barclays cut their target price on shares of Medline from $45.00 to $43.00 and set an “overweight” rating on the stock in a research note on Friday, October 9th. BTIG Research reissued a “buy” rating and issued a $55.00 price target on shares of Medline in a research note on Thursday, August 27th. William Blair restated an “outperform” rating on shares of Medline in a report on Wednesday, September 23rd. Tigress Financial lowered their price objective on shares of Medline from $62.00 to $55.00 and set a “buy” rating for the company in a report on Tuesday, August 11th. Finally, BMO Capital Markets reaffirmed an “outperform” rating and set a $47.00 price objective on shares of Medline in a research report on Thursday, August 6th. Two analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, four have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $46.54.

Medline Price Performance

The firm has a market cap of $53.05 billion and a PE ratio of 51.08. The company has a debt-to-equity ratio of 0.66, a current ratio of 4.33 and a quick ratio of 2.61. The firm has a 50-day simple moving average of $34.58 and a 200 day simple moving average of $39.53.

Medline (NASDAQ:MDLN) last released its earnings results on Wednesday, November 4th. The company reported $0.44 earnings per share for the quarter, topping analysts’ consensus estimates of $0.32 by $0.12. The business had revenue of $7.86 billion during the quarter. As a group, equities analysts expect that Medline will post 1.49 EPS for the current year.

Insider Buying and Selling

In related news, major shareholder Private Ltd Gic sold 2,088,987 shares of the business’s stock in a transaction dated Tuesday, October 6th. The shares were sold at an average price of $35.05, for a total transaction of $73,218,994.35. Following the sale, the insider owned 16,453,806 shares of the company’s stock, valued at $576,705,900.30. The trade was a 11.27% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders have sold a total of 8,538,960 shares of company stock worth $302,807,442 over the last 90 days. Insiders own 0.81% of the company’s stock.

Institutional Trading of Medline

A number of hedge funds have recently made changes to their positions in the stock. Healthcare of Ontario Pension Plan Trust Fund increased its position in Medline by 233.3% during the 1st quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 5,000,000 shares of the company’s stock valued at $222,500,000 after buying an additional 3,500,000 shares in the last quarter. Bessemer Group Inc. boosted its holdings in Medline by 39,404.0% in the first quarter. Bessemer Group Inc. now owns 3,504,006 shares of the company’s stock worth $155,929,000 after acquiring an additional 3,495,136 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its holdings in Medline by 30,255.5% in the third quarter. Allspring Global Investments Holdings LLC now owns 2,700,425 shares of the company’s stock worth $94,353,000 after acquiring an additional 2,691,529 shares in the last quarter. Bank of New York Mellon Corp purchased a new stake in shares of Medline in the second quarter worth $40,430,000. Finally, Janus Henderson Group PLC grew its stake in shares of Medline by 8.4% in the first quarter. Janus Henderson Group PLC now owns 11,451,861 shares of the company’s stock worth $506,546,000 after acquiring an additional 887,240 shares during the last quarter.

About Medline

Medline Industries, Inc is a medical-supply manufacturer and distributor headquartered in Northfield, Illinois. The company provides products and supply-chain services to healthcare organizations, including hospitals, ambulatory surgery centers, physician offices, long-term care facilities, home health providers and other care settings.

Its product portfolio includes medical-surgical supplies, surgical and operating-room products, patient-care items, examination gloves, protective apparel, laboratory products, respiratory-care equipment, durable medical equipment and products for infection prevention.